uniQure (NASDAQ:QURE) Shares Gap Down – Time to Sell?

uniQure (NASDAQ:QURE) gapped down prior to trading on Monday . The stock had previously closed at $12.47, but opened at $11.34. uniQure shares last traded at $10.38, with a volume of 548,019 shares trading hands.

Analysts Set New Price Targets

QURE has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. The Goldman Sachs Group increased their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Guggenheim reissued a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Leerink Partners raised their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. Finally, Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $20.00 to $52.00 in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $38.80.

uniQure Stock Down 6.5 %

The firm’s fifty day moving average price is $13.60 and its 200-day moving average price is $10.89. The firm has a market capitalization of $535.90 million, a P/E ratio of -2.00 and a beta of 0.37. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

Insider Activity at uniQure

In other news, CEO Matthew C. Kapusta sold 28,341 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total value of $291,628.89. Following the completion of the sale, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $11.32, for a total value of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This represents a 1.84 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 90,830 shares of company stock valued at $961,401. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. lifted its holdings in uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after buying an additional 969 shares in the last quarter. Tudor Investment Corp ET AL lifted its stake in shares of uniQure by 5.9% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock valued at $438,000 after acquiring an additional 1,371 shares during the period. Wells Fargo & Company MN boosted its holdings in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 1,503 shares during the last quarter. Northern Trust Corp boosted its holdings in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock valued at $1,688,000 after acquiring an additional 1,923 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in uniQure by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock worth $1,253,000 after purchasing an additional 3,996 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.